{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 23 of 51', 'Study ID RCB: 2020-A00652-37', 'outcome measure in randomised controlled trials in dermatology in general and in psoriasis', 'more specifically (Cardiff University, 2019; Puig et al., 2017).', 'The DLQI is composed of ten questions grouped in 6 domains \"symptoms and feelings\", \"daily', 'activities\", \"leisure\", \"work/school\", \"personal relationships\" and \"treatment\". To each', 'question the patient will have the followings choices: \"Very much\", \"A lot\", \"A little\", \"Not at', 'all\" or \"not relevant\"', 'Each answer is graded from 0 (\"not relevant\", \"not at all\" or not answered) to 3 (\"very much\").', 'The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and', 'a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than', \"10 indicates that the patient's life is being severely affected by their skin disease (Finlay and\", 'Khan, 1994).', 'More specifically, the total score will be divided into the following subcategories:', \"0-1 = no effect at all on patient's life;\", \"2-5 = small effect on patient's life;\", \"6-10 = moderate effect on patient's life;\", \"11-20 = very large effect on patient's life;\", \"21-30 = extremely large effect on patient's life.\", '9.1.4 Limitation of bias', 'In order to limit bias, the sensitivity and specificity analysis need to be performed on a', 'population as homogenous as possible. To this end, only patients treated with brodalumab', '(Kyntheum) will be enrolled. By doing so we will limit the bias due to different treatment', 'profiles (schedule of drug administration ). However, Kyntheum efficacy will not be', 'assessed during the study.', '9.1.5Study Schedule', \"The enrolment period is expected to be 5 months. After the patient's individual\", 'treatment plan has been decided, he/she will be approached for informed consent to', 'participate in the study and deliver data to use for national and pooled analysis.', 'Investigators are expected to enter data into the site specific part of the CRF at baseline and', 'at any patient contact throughout the duration of the study. In order to complete and sign-off', 'the CRF, a medical record may be used as source for historical data.', 'Visits will be according to local clinical practice and not decided in advance by the study', 'protocol.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 24 of 51', 'Study ID RCB: 2020-A00652-37', 'Relevant data from every visit within 52 weeks after baseline will be collected.', 'For analysis the following applies:', 'Visits that falls within week 12/-16 weeks are proxy for visit at 3 months. If more than one visit', 'within this period, the visit closest to week 16 will be used for analysis.', 'Visits that falls within week 48-56 weeks are proxy for visit at 12 months (52 weeks 4) .If', 'more than one visit within this period, the visit closest to week 52 will be used for analysis.', 'The study design is the following:', 'Baseline', '3 months', '12 months', '(week o, Day 1)', 'week 12/16', 'week 52 + 4', '1st follow-up visit', '2nd follow-up visit', 'Start of Kyntheum', 'treatment', 'The study will enrol consecutive patients planned to receive Kyntheum and fulfilling the', 'R', 'eligibility criteria. The assignment of the patient to Kyntheum must not be decided in advance', 'by the trial protocol, but must fall within current practice, and the prescription shall be clearly', 'separated from the decision to include the patient in the study. The visit schedule is defined', 'by the standard of care as there is no extra mandatory visits related to the participation in the', 'study. Patients must be informed about the study and asked for consent to use their data, and', 'patients willing to participate be enrolled.', '9.1.6 Definition of a non-interventional study', \"The study is a 'non-interventional study' as defined for drug studies in Directive 2001/20/EC\", '(European Commission, 2001) with primary data collection and will follow the guidelines for', 'Good Pharmacoepidemiology Practices (Public Policy Committee, 2016).', 'This means that:', 'The medicinal product is prescribed in the usual manner in accordance with the terms', 'of the marketing authorisation;', 'The assignment of the patient to a particular therapeutic strategy is not decided in', 'advance by a trial protocol but falls within current practice and the prescription of the', 'medicine is clearly separated from the decision to include the patient in the study', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 25 of 51', 'Study ID RCB: 2020-A00652-37', 'No additional diagnostic or monitoring procedures are applied to the patients.', 'Interviews, questionnaires, blood samples and patient follow-up may be performed as', 'part of normal clinical practice.', 'Epidemiological methods are used for the analysis of collected data.', '9.2 Setting', 'The study is planned to be conducted in approximatively 25 sites in 2 countries. Investigators', 'will be clinical dermatologists. Each participating site is expected to include in average 5/6', 'patients. In case of slow recruitment in some sites, the other sites will be allowed to enrol up', 'to 10 patients. Inclusion requires that Kyntheum is prescribed in accordance with the', 'approved terms of the marketing authorization in the country and that none of the stated', 'contraindications apply.', 'Caution should be taken by the treating physician concerning any precautions, warnings and', 'potential drug interactions stated in the product label.', 'Patients should be included in the study only once.', 'The study aims to involve sites and investigators that are representative for HCPs that prescribe', 'biologics to patients suffering from psoriasis vulgaris. Sites can be hospital (university, private,', 'public) dermatology departments, private dermatology clinics, and all sorts of general', 'practices. Sites where patients are prescribed Kyntheum, but for continuation of care are', 'routinely referred to a different site without access to prescribe Kyntheum, should not be', 'selected for this study.', 'Information about the PSO-TARGET study should be given after the decision is made to', 'treat the patient with Kyntheum It will be emphasized that the participation study will not', 'condition the patient treatment and will not alter the visit schedule defined by the standard', 'of care (3 and 12 months). After enrolment (i.e. signature of the Informed Consent Form), the', 'physician will provide the patient with the QoL component grid along with the DLQI', 'questionnaire. After having explained the purpose of the table in regards to the study, the', 'physician shall give the patient enough time to reflect on which component is the most', 'important for him/her without influencing him/her. Both questionnaires will be answered', 'after this reflection period.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}